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osting by EAbstract Compensated cirrhosis means that the liver is heavily scarred but can still perform many
important functions; many peoples with compensated cirrhosis have gall bladder stones. The advan-
tages of laparoscopic cholecystectomy (LC) for most patients have been extensively published.
However its beneﬁts and successful use in patients with cirrhosis are less documented.
The study compromised 50 patients with symptomatic gallstone in compensated liver disease and
undergone either open cholecystectomy (OC) or laparoscopic cholecystectomy. These patients were
randomized into two groups: Group I included 24 patients who underwent OC, and group II
included 26 patients who underwent LC. Patient’s age, sex, clinical presentation and Child-Tur-
cotte-Pugh (CTP) class were documented. No patients in this study had CTP class c cirrhosis.
IL-6 was measured by ELISA, postoperative pain (measured by Visual analog scale), hospital
stay, blood loss, recovery time (return to work), and liver function tests were documented.
IL-6 was signiﬁcantly lowered at 6th hour and 12th hour post operative in LC group.Mean surgical
time was signiﬁcantly longer in OC than LC group, (mean ± SD, 96.6 ± 32 vs 58.7 ± 23.8 min,
P= 0.037). No patients in group II required any blood replacement in contrast to 9 patients9334743.
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190 E. Ragab et al.(37.5%) in group I. Intraoperative bleeding remained signiﬁcantly higher in group I (P= 0.043). No
patients in group II had wound complications compared with 5 patients (29.14%) in group I. Group I
had signiﬁcantly longer hospital stay than group II, mean 9.0 + 1.3 days (median 7) vs 2.3 days +
1.9 (median 2.5); P= 0.001.
Our results were demonstrated that laparoscopic cholecystectomy can be performed safely in
patients with CTP class A and B cirrhosis. IL-6 was more signiﬁcantly, increased post operatively
in open cholecystectomy than laparoscopic one and it correlated well with intensity of operative
trauma.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) infection affects an estimated 170 mil-
lion individuals worldwide, and 5 million in the United States,
where it is currently recognized as the most prevalent blood-
borne infection and the leading indication for a liver transplant
[1].
Treatment of HCV with pegylated interferon-a-2a is suc-
cessful in eradicating virus from only 30% to 80% of those
treated, with individuals infected with the more resilient geno-
type-1 virus having markedly lower response rates than those
with non-genotype-1 infections. Additionally, differences in
outcome have been described by race, with African Americans
having signiﬁcantly lower response rates than Caucasian
Americans [2–4].
Expressed in a number of different cell types, including,
hepatocytes, macrophages, B-cells and T-cells, interleukin-6
(IL-6) is a pleiotropic cytokine important in the immunologic
response to infections. IL-6 plays an important role in HCV
infection as well as the response to IFN therapy. In addition
to interacting with crucial components of the interferon re-
sponse pathways, IL-6 is an activator of acute phase proteins
in hepatocytes. A recent study has suggested the potential
importance of IL-6 in the treatment response of HCV patients
to interferon-based therapy [5].
It has been reported that the degree of post operative
inﬂammation is reduced after laparoscopic surgery. Other
groups also observed signiﬁcantly better preservation of lym-
phocytes subpopulations, neutrophil function, and cell-medi-
ated immunity after laparoscopic vs open colorectal surgery.
Furthermore, it has been observed that cell-mediated immu-
nity, as assessed by delayed-type hypersensitivity testing in hu-
mans, is better preserved after laparoscopic vs open colorectal
resection. This lesser degree of operative stress was also con-
ﬁrmed by experimental animal studies by Matthias et al. [6].
Infection with hepatitis C virus (HCV) has become the most
important public health problem in Egypt.
There is a high incidence of anti-HCV seropositivity among
the Egyptian population, with an overall age-adjusted preva-
lence of HCV antibodies of 21.9% [7]. Schistosoma mansoni
(SM) is endemic in Egypt. The prevalence of Schistosoma
mansoni in the Nile River Delta extends to 45% of the popu-
lation [8]. Chronic viral hepatitis C and infection with SM are
the two major causes of chronic liver disease in Egypt [9].
Gallstones are twice more prevalent in patients with cirrho-
sis than in the general population [10]. Factors implicated in
the higher incidence of gall stone formation include hyper-
splenism, increased levels of estrogen, and increased intravas-
cular hemolysis with reduction in gall bladder emptying and
motility [11,12].The technical challenge and risk of performing open chole-
cystectomy (OC) in patients with compensated cirrhosis and
symptomatic gall stone disease have been well documented
[13,14]. The severity of cirrhosis assessed with Child-
Turcotte-Pugh (CTP) classiﬁcation, is a major determinant in
deciding which treatment approach is optimal. Since the intro-
duction of laparoscopic cholecystectomy (LC), a controversy
regarding which procedure is preferable for patients with
cirrhosis has arisen [15,16].
Several studies reported good results and suggested liberal
use of LC in patients with early-stage cirrhosis and symptom-
atic gall stone disease [17,18]. No deﬁnite data have been of-
fered to prove LC should be the ﬁrst surgical line in patients
with cirrhosis [19]. The present study is a prospective analysis
comparing the results of OC and LC in patients with compen-
sated cirrhosis and symptomatic gall stone disease. The pur-
pose of this study was to compare the risks and beneﬁts of
performing open cholecystectomy (OC) and laparoscopic cho-
lecystectomy (LC) in patients with compensated cirrhosis, and
role of IL-6 post operative.
2. Patients and methods
This study included 50 patients with hepatic cirrhosis and
symptomatic gall stones disease who underwent cholecystec-
tomy at Mansoura University Hospital, Mansoura, Egypt.
These patients were subjected to a thorough history and clini-
cal examination focused on manifestation of gall stone disease
and chronic liver disease.
The following laboratory investigations were performed:
urine and stool analysis; liver function tests (serum bilirubin,
ALT, AST, prothrombin time, INR and serum albumin);
whole blood picture; kidney function tests; HCV and HBV
markers.
The diagnosis of schistomiasis was based upon positive
stool analysis or positive rectal snip for schistosomal egg. A
history of repeated antischistosomal treatment and/or positive
indirect hemagglutination assay (IHA) for schistomiasis indi-
cated previous exposure [20]. Patients positive for schistosoma
mansoni (SM) with negative viral markers were considered
pure SM. Patients with positive anti HCV antibodies, high li-
ver enzymes, positive HCV by RT-PCR, and negative for
schistomiasis were assigned to the pure HCV group. Patients
positive for both HCV and schistomiasis constituted up the
mixed (HCV + S) group. Patients positive for HBV and neg-
ative for HCV are considered pure HBV group. Patients posi-
tive for both HCV and HBV made up the mixed
(HCV+ HBV) group.
HCV-RNA analysis was done on serum samples that had
been stored at 70 C immediately after collection. In brief,
Figure 2 A case of hepatitis C showing focal liver cell necrosis
replaced by inﬂammatory cells (H & E ·100).
Figure 3 A case of hepatitis B showing ground glass hepatocytes
(H & E ·100).
Interleukin 6 (IL6) as a predictor outcome 191extracted RNA was converted into cDNA that was used as a
template for PCR ampliﬁcation using primer sequences de-
rived from highly conserved 50-non-coding region of the gen-
ome (outer primers: sense 50-CCA TGG CGT TAG TAT
GAG TG-3, anti-sense 50 TGC TCA TGG TGC ACG GTC
TA-3 and inner primers: sense 50-AGA GCC ATA GTG
TGC GG-30, anti-sense 50-CTT TCG CGA CCC AAC ACT
AC-30).
HCV genotypes for all patients were performed by reverse
transcription polymerase chain reaction (RT-PCR) using spe-
ciﬁc primers. The typing assay is based on a ﬁrst outer PCR
utilizing consensus primers to amplify the 284 bp segment of
the HCV core gene. Thereafter 1.0 ml of the ﬁrst PCR product
is used as a target in a second PCR with one consensus up-
stream primer and four type speciﬁc downstream primers, each
giving a product of a type speciﬁc size.
Genotypes of HCV were distinguished from each other by
the size of product: 52 bp for type I, 141 bp for type II,
173 bp for type III, and 126 bp for type IV. The diagnosis of
cirrhosis had been proven on clinical basis, laboratory results,
macroscopic intra-operative appearance and liver biopsy (15
patients preoperative and 13 patients intra-operative). The pre-
pared slides were examined by a pathologist to detect and stage
ﬁbrosis as described by Knodel et al. [21] and the histopatho-
logic activity index based on the assessment of portal inﬂam-
matory inﬁltrate, interface hepatitis and parenchymal
necrosis ( Figs. 1–4). The diagnosis of gall bladder lithiasis
had been determined in all patients by clinical history and
abdominal ultrasonography.
Pathological processing for liver biopsy specimen was as
follows: 4 mm sections were prepared from parafﬁn blocks
and stained for hematoxyline and eosin stain, masson tri-
chrom. Reticulin, PAS and PAS-diastase stains.
HBsAg and HBcAg immunochemistry were applied rou-
tinely to all liver biopsy specimens. Monoclonal antibody to
HBsAg and polyclonal antibody for HBcAg were applied
(Zymed, South San Francisco, CA). Any positive cases for
HBV were excluded. Prepared slides from liver biopsy speci-
men were examined blindly by the pathologist. Degree of necr-
oinﬂammatory injury and stage of ﬁbrosis were assessed
according to [21], however, with modiﬁcation. Histologic
activity index (HAI) is based upon the assessment of portal
inﬂammatory inﬁltrate, interface hepatitis and parenchymal
necrosis, with score range from 0 to 18. It was considered asFigure 1 A case of chronic hepatitis with marked activity and
cirrhosis showing interface hepatitis with marked lymphocytic
inﬁltration (H & E ·40).
Figure 4 Liver biopsy with Schistosomal granuloma with central
bilharzial ovum in the portal area (H & E ·100).minimal (1–3), mild (4–8), moderate (9–12) and severe (13–
18). Fibrosis is staged separately on a scale of 0–4, correspond-
ing to absent ﬁbrosis up to cirrhosis (based on Desmet system).
Randomization was carried out using presealed envelops
immediately before the surgery.
The Child-Turcotte-Pugh classiﬁcation system was used to
assess the severity of cirrhosis. No patients in this study had
CTP class C cirrhosis. All operations were performed under
general anesthesia; hepatotoxic drugs were avoided. Estimated
intra-operative bleeding was recorded from surgical reports,
and blood loss was classiﬁed as less than 200 ml, 200–500 ml,
Table 2 Etiology of liver disease.
Etiology OC group LC group
n (24) % n (26) %
Mixed HBV & HCV 3 12.5 3 11.54
Pure HBV 1 4.17 2 7.69
Pure schistosomal 3 12.5 4 15.38
Pure HCV 9 37.5 11 42.31
Mixed schistosomal & HCV 7 29.17 7 26.92
HCV= hepatitis C virus.
HBV= hepatitis B virus.
Table 3 Severity of hepatic cirrhosis.
CTP OC group LC group
n (24) % n (26) %
A 17 71 22 85
B 7 29 4 15
C 0 0 0 0
CTP = Child-Turcotte-Pugh.
Table 4 Surgical time and hospital stay.
OC group LC group P value
n (24) n (26)
Surgical time (min)
Mean ± SD 96.6 ± 32 58.7 ± 23.8 <0.05
Range 50.0–137 47–116
Hospital stay (day)
Mean + SD 9.0 ± 1.3 2.3 ± 1.9 <0.05
Range 3–7 1–8
192 E. Ragab et al.and more than 500 ml. Blood replacement was also docu-
mented. Surgical and anesthetic times were documented as
intraoperative ﬁndings, perioperative complications, and
length of hospital stay. A standard laparoscopic procedure
was used for all patients, as described by [22].
Conventional cholecystectomy employed a 13 cm subcostal
incision (10 patients) or upper right paramedian incision (14
patients). Post operative subjective pain score on mobilization
using the VAS (Visual analog scale) was recorded on the 1st,
3rd, 7th, post operative days [23]. Also the serum interleukin-
6 was measured at the 6 h, and the 12 h, post operative using
immunoassay.
IL-6 assay by ELISA (Titrezyme perspective biosystem):
2 ml of blood sample was withdrawn from all subjects under
sterile condition, centrifuged at 3000 rpm for 15 min and the
non-hemolyzed serum was separated and preserved at
70 C till cytokine assay. Circulating serum IL-6 level was
determined using ELISA assays as described by the manufac-
turer. The patients are followed up weekly for the 1st month,
monthly for the ﬁrst three months and every three months
for a range of 12 months to 36 months, clinically, laboratory
(liver function test) and radiological (abdominal ultrasound).
Statistical comparison between the OC and LC groups was
made with Fisher’s exact test for variables with continuous
or ordinal distribution.
3. Results
The patients demographic data, and clinical presentation of
gall bladder disease, etiology of liver disease, and its severity
are shown (Tables 1–3). Three cases were converted from lap-
aroscopic into open cholecystectomy (one patient due to dense
vascular adhesions, patients due to difﬁcult dissection of Cal-
oˆts triangle and another patient due to uncontrollable liver
bed bleeding). Table 4 showed shortened surgical time and
hospital stay for LC group in comparison to OC group
(P< 0.05). There was a signiﬁcant intraoperative blood loss
in OC group (P< 0.05). Ten patients were in need of blood
transfusion ranging from 1 to 2 units, but the estimated post
operative blood loss was statistically insigniﬁcant between
both groups (Table 5). Table 6 showed a signiﬁcant reduced
pain (subjective) score in LC group and similarly less burden
on the patients metabolic response as reﬂected by loweredTable 1 Patient’s demographics data.
Patients OC group
n (24) %
Age
Mean + SD 42.3 + 15.3
Sex
Male 10 41.7
Female 14 58.3
Clinical presentation
Acute cholecystitis 2.0 8.3
Biliary colic 22.0 91.7
NS = non-signiﬁcant.
OC = open cholecystectomy.
LC = laparoscopic cholecystectomy.IL-6 level at the 6th hour and the 12th hour post operative
(P< 0.05). No operative mortality in both groups. Lastly
Table 7 showed patients morbidity which is more frequent in
OC group than LC group (P< 0.05), with statistically signif-
icant difference as regard to readmission in OC group (three
patients with encephalopathy, one patient with ascetic ﬂuidLC group P value
n (26) %
40.6 + 14.1 NS
10 38.5 NS
16 61.5
1 3.8 NS
25 96.2
Table 5 Intra & post operative blood loss (mL).
OC group LC group P value
n (24) % n (26) %
Intra operative loss
<200 9 37.5 20 76.9 <0.05*
200–500 6 25 4 15.4
>500 9 37.5 2 7.7
Blood transfusion
Yes 10 41.7 0 0.0 <0.05*
No 14 58.3 26 100
Post operative loss
<200 20 83.33 25 96.15 NS
200–500 2 8.3 1 3.84
>500 2 8.3 0 0
NS = non-signiﬁcant.
* = Signiﬁcant.
Interleukin 6 (IL6) as a predictor outcome 193leak, one patient with wound hemorrhage, and one patient
with wound infection necessitating debridment) and deteriora-
tion of liver function in OC group. Although bile leakage was
more common in LC group (11.5%) but it showed no signiﬁ-
cant value.
4. Discussion
Chronic liver disease represents a major cause of morbidity
and mortality worldwide. The major etiologies are chronicTable 6 Post operative pain and interleukin-6 (U/mL).
OC group
Mean ±SD
Post operative pain
1st day 8.7 0.77
3rd day 5.46 0.47
7th day 4.41 0.73
Post operative IL-6 Mean Range
6th hour 1150 1250–750
12th hour 900 1100–700
Table 7 Patients morbidity.
OC group
n (24) %
Morbidity 16 60
Pulmonary infection 3 12.
Urine retention 2 8.3
Deterioration of liver function 8 40
Ascitic ﬂuid leak 4 16.
Bile leakage 1 4.2
Encephalopathy 1 4.2
Wound complications
Hemorrhage 2 8.3
Infection 5 20.
Readmission 6 25
Incisional hernia 4 16.
NS = non-signiﬁcant.
P< 0.05 = signiﬁcant.infection with hepatitis B (HBV) and C (HCV) viruses, and
alcoholic and non-alcoholic fatty liver disease. Chronic hepati-
tis B and C are the leading causes of cirrhosis and of hepato-
cellular carcinoma worldwide. Approximately 400 million
people are chronically infected with HBV and 25–40% of them
die of cirrhosis and of its end-stage complications [24].
HBV is the most important carcinogen after tobacco and
the incidence of hepatocellular carcinoma is 300,000 cases
per year [25]. Chronic hepatitis C is a major health concern
with around 200 million individuals affected worldwide, with
a greater prevalence in Western countries. Natural history
studies indicate that advanced ﬁbrosis and cirrhosis develop
in about 20–40% of patients with chronic viral hepatitis [12].
Since the ﬁrst laparoscopic hepatic lobectomy performed by
Reich in 1991, the laparoscopic operation procedure has been
practiced in the hepatobilliary surgery [16,26]. Because of the
abundant blood supply for the liver and pneumoperitoneum,
hemorrhage and gas embolism often occur during operation
[27]. Laparoscopic hepatic lobectomy is an operation proce-
dure with high difﬁculties and risks [28].
However, in recent years, with the development of laparo-
scopic instrument and operative skills, laparoscopic hepatic
lobectomy has gradually become a common operation proce-
dure in clinical practice [29,26]. It has many advantages over
the traditional open operation. In the traditional open opera-
tion, T-pieces should be placed in the common bile duct to
drain the bile after exploration of the common bile duct, which
provides channels for surgeon to take out the possible remnant
gallstones. However, it also bring about heavy burdens on the
patients, such as prolonged hospitalization time, unbalanceLC group P value
Mean ±SD
3.9 0.41 <0.05
2.1 0.35 <0.05
1.3 0.48 <0.05
Mean Range
450 550–450 <0.05
400 500–320 <0.05
LC group P value
n (26) %
8 30.7 <0.05
5 1 3.8 NS
0 0 NS
4 15.4 <0.05
7 1 3.8 NS
4 11.5 NS
0 0 NS
1 3.8 NS
8 0 0 <0.5
0 0 <0.5
7 0 0
194 E. Ragab et al.between electrolytes and digestive dysfunction caused by the
T-piece, complicated care for the T-piece. Researchers have
tried to solve these problems for a long time. In the early
1980s, open cholecystectomy in patients with cirrhosis was
associated with a post operative mortality ranging from 7%
to 26% [30–33]. Excessive blood loss, post operative liver fail-
ure, and sepsis were responsible for most of these deaths [34].
The importance of stratifying patients according to CTP
criteria as a method to predict perioperative complications
was clearly demonstrated. By the late 1980s better surgical
results had been published for cirrhotic patients with normal
hepatic synthetic function who underwent elective cholecystec-
tomy [10,13]. Open cholecystectomy was subsequently consid-
ered an acceptable therapeutic option in patients with CTP
class A and B cirrhosis. If the patient had class C cirrhosis
and symptomatic gallstone disease, attempts were made to
improve the patient’s hepatic function and control of ascitis
to allow for a safer elective operation [35,36]. Since the intro-
duction of LC, question of whether cirrhotic patients might
beneﬁt from this less invasive approach has been arisen, but
not fully answered. Several recent studies [32,37,35,38,14] have
demonstrated that LC in Child A and B cirrhosis was safer and
better tolerable than OC.
There were less incision-related complications, no mortal-
ity, low morbidity, shorter operative time and hospital stay
and fewer transfusion requirements [18,19]. In this study the
absence of mortality and low morbidity in the laparoscopic
group conﬁrms the privileged indication of laparoscopic chole-
cystectomy in cirrhotic patients, also the low conversion rate
was similar to non-cirrhotic patients which narrow the spec-
trum of conversion and enhance laparoscopist to maintain
that low conversion threshold. These data also conﬁrmed by
Marino, and Saeki et al. [37,39]. Also the shortened surgical
time of laparoscopic group with meticulous surgical procedure
and the shortened hospital stay is related to less morbidity and
better local and systemic responses (physiologic, immunologic
and metabolic) to this minimal invasive surgery [18].
In this study the reduced blood loss in the laparoscopic
group, whether operative or postoperative, is related to the
meticulous dissection (magniﬁed surgical ﬁeld) and the pneu-
moperitoneum barohemostatic effect. These data correlate
with the ﬁnding of [15,19,40,38]. The serum Il-6 level postop-
eratively was signiﬁcantly increased, more in open cholecystec-
tomy than laparoscopic one. These data proved that the serum
IL-6 correlates well with the intensity of operative trauma [41–
43]. The low subjective pain threshold and low objective inter-
leukin 6 levels in LC group signify less body physiologic re-
sponse to this minimal invasive procedure and support its
liberal use in these fragile patients as reported by [44,6]. Simi-
larly the absence of intraoperative intestinal retraction and less
pain in the laparoscopic group explain the low occurrence of
postoperative ileus and urine retention [45]. Moreover the ab-
sence of parietal incision in the laparoscopic group declines the
incidence of pulmonary complications, incisional hernia, and
readmission. These ﬁndings also reported by [46].
Also the reduced bleeding, intraoperative and postopera-
tive, minimal dissection and shorter operative time explain
the lack of deterioration in liver function [47,14]. Nevertheless
the shortened hospital stay, less morbidity and absent readmis-
sion decrease the total patient costs similar to those reported
by [48]. Lastly laparoscopy as an alternative to open cholecys-
tectomy is both beneﬁcial to the patient and the surgeon.Laparoscopic cholecystectomy in cirrhotic patients prevents
the hypervascular adhesions that contraindicate orthotopic li-
ver transplant [49] and lessen the contamination risk to the
medical and paramedical personnel [50].
5. Conclusion
An elective LC should be considered for every patient with
CTP class A or B cirrhosis and symptomatic gallstone to pre-
vent minimized biliary tract complications and the procedure
had a better outcome (less mortality and morbidity), shortened
operative time and less hospital stay, tolerable loco-systemic
body response, wide range of safety (neither decomposition
nor prevent orthotopic liver transplant), less economic, and
preserve surgeon’s safety.
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